New lupus injection enters first human safety tests

NCT ID NCT06144710

First seen Mar 28, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This study is an early test of an experimental drug called SG301, given as an injection under the skin. It will first be tested in 48 healthy adults to check safety, then in people with systemic lupus erythematosus (SLE), an autoimmune disease. The main goal is to see if the drug is safe and to find the right dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, 361003, China

  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, 330006, China

  • Jining First People's Hospital

    Jining, Shandong, 272002, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, 337099, China

  • Shandong University Qilu Hospital

    Jinan, Shandong, 250063, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, 518020, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, 233000, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, 350004, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 314408, China

Conditions

Explore the condition pages connected to this study.